Trial Profile
Extension Study of WT4869 in Patients with Myelodysplastic Syndromes (MDS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs WT 4869 (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 23 Feb 2017 Status changed from active, no longer recruiting to completed.
- 06 Jun 2016 New trial record